Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free
Close

Editas Medicine Inc (EDIT)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Editas Medicine's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
12.75 +0.22    +1.76%
06/10 - Closed. Currency in USD ( Disclaimer )
Pre Market
12.21
-0.54
-4.24%
8:33:17 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,146,218
  • Bid/Ask: 12.22 / 13.63
  • Day's Range: 12.33 - 12.95
Editas Medicine 12.75 +0.22 +1.76%

EDIT Earnings

 
The latest earnings per stock, revenues and financial reports for Editas Medicine (EDIT).
InvestingPro Earnings Insights
Latest Release

Aug 03, 2022

EPS / Forecast

-0.78 / -0.8083

Revenue / Forecast

6.4M / 4.29M

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Mar 07, 2023 12/2022 -- /  -0.888 -- /  4.7M
Nov 09, 2022 09/2022 -- /  -0.8472 -- /  4.73M
Aug 03, 2022 06/2022 -0.78 /  -0.8083 6.4M /  4.29M
May 04, 2022 03/2022 -0.74 /  -0.7817 6.77M /  3.85M
Feb 24, 2022 12/2021 -0.61 /  -0.7122 12.47M /  4.64M
Nov 08, 2021 09/2021 -0.57 /  -0.8129 6.2M /  4.74M
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View upcoming earnings forecasts and in-depth analysis of company forecasts.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

EDIT Comments

Write your thoughts about Editas Medicine Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Khalifa Almannaei
Khalifa Almannaei May 18, 2022 5:24AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Bullish
Reply
4 1
Report
Gregg Alvarez
Gregg Alvarez Mar 22, 2022 5:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I waited for over a year to come to what I think is a steal. I thought it was never going to happen, honestly. Haha. Got some nice swing trades though. Hoarded a lot below 15. I hope this is a bottom. If not, oh well. Personally, I think this is a
Reply
0 0
Report
andrew mccorkle
andrew mccorkle Mar 22, 2022 5:18PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
mk9>98
Reply
0 0
Report
steve barone
steve barone Oct 08, 2021 6:17PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
this company's stock price needs to start moving in the upward direction!
Reply
1 1
Report
Meet Bryan
Meet Bryan Oct 07, 2021 1:31PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
the Company will present preclinical data on its progress in the development of cell therapy medicines for the treatment of cancer at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting being held in Washington, D.C., and virtually, November 10-14, 2021.The Company will present a poster on its new method to drive high-level constitutive CD16 expression on the surface of iPSC-derived natural ***(iNK) cells through transgene knock-in (KI) at the GAPDH locus using an Editas-engineered AsCas12a. New preclinical data demonstrated that CD16 KI confers significantly increased cytotoxic activity in iNK cells against tumor cells compared with wild type iNK cells.
Reply
1 1
Report
Meet Bryan
Meet Bryan Oct 07, 2021 10:23AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
this 37 dollar price point seems to me a very strong support.
Reply
2 0
Report
TRDA AAL
TRDA AAL Sep 29, 2021 2:04PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
is it worthy to invest in this stock?
Reply
0 0
Report
Willy Tsai
Willy Tsai Sep 29, 2021 2:04PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
No
Reply
0 0
Report
Christian Rasmussen
Christian Rasmussen Sep 29, 2021 9:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I don't get it. Fantastic results, and the shareprice drops like a rock!?
Reply
3 0
Report
Meet Bryan
Meet Bryan Sep 29, 2021 9:50AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
well, now it is looking like a buy at 38 dollar. There is a very strong trendline there
Reply
1 0
Report
Meet Bryan
Meet Bryan Sep 29, 2021 8:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Today is the day.
Reply
1 0
Report
Yasser Abdulhadi
Yasser Abdulhadi Sep 29, 2021 8:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
For what exacty !!!
Reply
0 0
Report
Meet Bryan
Meet Bryan Sep 29, 2021 8:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
for positive research results on low and mid dose + a sell off xD
Reply
1 0
Report
Mustafa Mond
Mustafa Mond Sep 14, 2021 12:13PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ark invest sold 90,000 share of editas
Reply
0 0
Report
Meet Bryan
Meet Bryan Sep 10, 2021 10:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. ET. Editas Medicine, a leading genome editing company, announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the XIXth International Symposium on Retinal Degeneration
Reply
0 0
Report
Meet Bryan
Meet Bryan Sep 10, 2021 10:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Results on september 29th , not september 10 th
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email